Tim Smith

In the February edition of Dermatology Month in Review, new acne guidelines released by AAD, an FDA decision on nemolizumab, and an interview on potentially the first oral IL-23 inhibitor for psoriasis were among the major stories.

These findings suggest much lower prices can be achieved for medications, with better alignment to the benefits of different biological psoriasis treatments.

In honor of Rare Disease Day, this exploration of prurigo nodularis highlights the skin disease’s psychosocial impact on patients around the world living with the condition.

This analysis presented at AAAAI suggests that the experimental OMIT delivery of allergens via toothpaste may allow for a safer alternative to other immunotherapies.

This analysis emphasizes the necessity of prevention of melanoma as well as the public health and economic consequences of patients’ delaying of skin cancer diagnoses.

In this Q&A discussion, Bhatt discusses the recent news of dupilumab’s supplemental Biologics License Application for COPD patients with type 2 inflammation, as well as its significance.

These new data from BioCryst, presented at AAAAI, suggest that patients treated with berotralstat may see substantial decreases in HAE attacks.

Twelve evidence-based Key Action Statements were provided for clinicians to guide them in the treatment of patients reporting inhalant allergy symptoms.

In an interview during the 2024 AAAAI conference, Casale addressed his team’s findings regarding epinephrine nasal spray and its effectiveness with regard to exacerbations of urticaria.

These findings may allow for patients with severe allergic reactions to have an alternative to epinephrine auto-injector devices.

In this interview, Ebisawa discusses his team’s recent research into the frequently-discussed non-injector epinephrine alternative neffy.

These findings, to be presented at AAAAI, may help to expand upon clinicians’ awareness of the mechanics of air pollution’s effect on asthma.

The FDA’s decision is planned for June 2024, and follows the successful results of the BOREAS and NOTUS trials.

This analysis, to be presented at AAAAI, suggests that adolescents’ attendance of daycare may lead to decreased IgE levels and diminished food and aeroallergen sensitization rates.

This analysis suggests that the financial burden of oral food challenges may be offset slightly through the use of FPIES.

These data, to be presented at AAAAI, indicate that following 12 and 24 months of immunotherapy with BMOIT, desensitization to milk products can be observed among patients.

These findings, to be presented at AAAAI, may allow for greater awareness among clinicians when prescribing eczema therapies.

These findings, to be presented at AAAAI, highlight the importance of labeling different cleansing products used by consumers with eczema.

Additional research may be necessary to look at the sequence of epinephrine administration and advanced airway management in settings in which alternative epinephrine administration strategies are utilized.

Additional validation of such improvement thresholds using unblinded trial data may be necessary to allow for more evidence of their utility in clinical research and practice.

In this Lungcast segment, Spicer spoke on several treatment-specific biomarkers for lung cancer and discussed the future of lung cancer therapy.

During this segment of his interview, Bissonnette discussed safety data on JNJ-2113 for patients with plaque psoriasis and later went into future research topics.

In this interview, Bissonnette spoke on the significance of the recent topline data on JNJ-2113 for patients with plaque psoriasis.

The approval is based upon phase 3 findings from the OUtMATCH study, representing the first treatment for adult and pediatric patients with accidental exposure to 1 or more food allergens.

Additional research on this form of moisturizer and other ingredients for acne with larger sample sizes may be needed to verify efficacy for acne vulgaris.

This research also included results from a sub-analysis of non-responders with hand eczema to dupilumab and upadacitinib.

This segment of Lungcast features a discussion with Spicer about the timing of lung cancer treatment, as well as evolution of adjuvant and neoadjuvant therapies.

In addition to the newly-accepted BLA in the US, the European Medicines Agency also accepted the drug’s Marketing Authorization Application for both conditions.

For patients with chronic rhinosinusitis, seasonal allergies may only make the condition feel worse for patients, though the relationship is still poorly defined.

The findings in a recent phase 3 clinical study may allow Kalvista Pharma to seek FDA approval for this potential hereditary angioedema treatment option.